---
title: "Exponent | 8-K: FY2027 Q4 Revenue: USD 147.43 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275029695.md"
datetime: "2026-02-05T21:09:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275029695.md)
  - [en](https://longbridge.com/en/news/275029695.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275029695.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275029695.md) | [繁體中文](https://longbridge.com/zh-HK/news/275029695.md)


# Exponent | 8-K: FY2027 Q4 Revenue: USD 147.43 M

Revenue: As of FY2027 Q4, the actual value is USD 147.43 M.

EPS: As of FY2027 Q4, the actual value is USD 0.49.

EBIT: As of FY2027 Q4, the actual value is USD 27.2 M.

### Fourth Quarter Fiscal Year 2025 Financial Results (13 weeks ended January 2, 2026, compared to 14 weeks ended January 3, 2025)

#### Revenue

-   Total revenues increased 7.8% to $147.4 million, up from $136.8 million in the prior year period.
-   Revenues before reimbursements increased 4.5% to $129.4 million, up from $123.8 million in the prior year period.

#### Net Income

-   Net income increased to $24.8 million, compared to $23.6 million in the prior year period.

#### Operating Profit and Margin

-   Operating income was $29.14 million, compared to $27.253 million in the prior year period.
-   EBITDA increased to $34.7 million, or 26.8% of revenues before reimbursements, compared to $31.2 million, or 25.2% of revenues before reimbursements, in the prior year period.

#### Operating Costs

-   Total operating expenses were $118.285 million, compared to $109.513 million in the prior year period.

#### Segment Performance

-   The Engineering and Other Scientific segment represented 85% of revenues before reimbursements, with revenues before reimbursements increasing 7%.
-   The Environmental and Health segment represented 15% of revenues before reimbursements, with revenues before reimbursements decreasing 5%.

### Fiscal Year 2025 Financial Results (52 weeks ended January 2, 2026, compared to 53 weeks ended January 3, 2025)

#### Revenue

-   Total revenues increased 4.2% to $582.0 million, up from $558.5 million in the prior year.
-   Revenues before reimbursements increased 3.5% to $536.8 million, up from $518.5 million in the prior year.

#### Net Income

-   Net income was $106.0 million, compared to $109.0 million in the prior year.

#### Operating Profit and Margin

-   Operating income was $119.787 million, compared to $119.557 million in the prior year.
-   EBITDA increased to $148.1 million, or 27.6% of revenues before reimbursements, compared to $147.1 million, or 28.4% of revenues before reimbursements, in the prior year.

#### Operating Costs

-   Total operating expenses were $462.227 million, compared to $438.957 million in the prior year.

#### Cash Flow and Capital Allocation

-   毅博科技咨询 (Exponent, Inc.) paid $61.5 million in dividends during fiscal year 2025.
-   The company repurchased $97.8 million of common stock during fiscal year 2025.
-   毅博科技咨询 (Exponent, Inc.) ended the year with $221.9 million in cash and cash equivalents, compared to $258.901 million in the prior year.

#### Operational Metrics

-   Headcount increased sequentially and was up approximately 4% for the year.
-   Fourth quarter utilization improved on a year-over-year basis.

#### Segment Performance

-   The Engineering and Other Scientific segment represented 84% of revenues before reimbursements, with revenues before reimbursements increasing 4%.
-   The Environmental and Health segment represented 16% of revenues before reimbursements, with revenues before reimbursements being approximately flat.

#### Dividends

-   毅博科技咨询 (Exponent, Inc.) increased its quarterly cash dividend from $0.30 to $0.31 per share of common stock for Q1 2026.
-   This quarterly cash dividend of $0.31 per share is scheduled to be paid on March 20, 2026, to all common stockholders of record as of March 6, 2026.

#### Business Outlook

-   For the first quarter of fiscal year 2026, 毅博科技咨询 (Exponent, Inc.) anticipates revenues before reimbursements to grow in the high-single digits and EBITDA to be 27.5% to 28.5% of revenues before reimbursements.
-   For the full fiscal year 2026, the company expects revenues before reimbursements to grow in the high-single digits and EBITDA to be 27.6% to 28.1% of revenues before reimbursements.
-   Management expressed confidence in continued profitable growth, supported by strong market drivers and the company’s operating model, and expects to continue paying quarterly dividends.

### Related Stocks

- [Exponent, Inc. (EXPO.US)](https://longbridge.com/en/quote/EXPO.US.md)

## Related News & Research

- [Exponent's Q4 revenue rises 7.8%, beats expectations](https://longbridge.com/en/news/275032005.md)
- [Assessing Exponent (EXPO) Valuation After Recent Share Pullback And Mixed Growth Expectations](https://longbridge.com/en/news/279476304.md)
- [Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights | RVPH Stock News](https://longbridge.com/en/news/280996019.md)
- [Wealth First Promoters Confirm 74% Stake With No Encumbrance in FY26](https://longbridge.com/en/news/281530653.md)
- [Key facts: Bunge Increases Securitization to $2.0B; 8-K on Obligation](https://longbridge.com/en/news/281659964.md)